ⓘ Enoblituzumab

                                     

ⓘ Enoblituzumab

Enoblituzumab is a monoclonal antibody designed for the treatment of cancer. Formerly known as MGA271, the drug is a humanized IgG1κ monoclonal antibody recognizing human B7-H3, a member of the B7 family of immune regulators.

This drug developed by MacroGenics, Inc. in

                                     
  • nectin - 4 Y urothelial cancer Enlimomab pegol mab mouse ICAM - 1 CD54 Enoblituzumab mab humanized CD276 cancer Enokizumab mab humanized IL9 asthma Enoticumab